| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 54 | 2022 | 4946 | 2.820 |
Why?
|
| Antiretroviral Therapy, Highly Active | 16 | 2015 | 468 | 2.350 |
Why?
|
| Anti-HIV Agents | 20 | 2021 | 1275 | 2.000 |
Why?
|
| Tuberculosis | 10 | 2022 | 530 | 1.930 |
Why?
|
| Anti-Retroviral Agents | 6 | 2015 | 542 | 1.520 |
Why?
|
| HIV-1 | 25 | 2019 | 1239 | 1.420 |
Why?
|
| Child | 38 | 2023 | 2180 | 1.290 |
Why?
|
| Child, Preschool | 39 | 2019 | 1675 | 1.290 |
Why?
|
| Viral Load | 18 | 2019 | 808 | 1.110 |
Why?
|
| Ritonavir | 9 | 2015 | 137 | 0.970 |
Why?
|
| Rifampin | 6 | 2021 | 189 | 0.910 |
Why?
|
| Infant | 35 | 2015 | 2145 | 0.890 |
Why?
|
| HIV Protease Inhibitors | 7 | 2012 | 92 | 0.870 |
Why?
|
| HIV | 8 | 2021 | 380 | 0.830 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2019 | 47 | 0.820 |
Why?
|
| Lopinavir | 10 | 2015 | 137 | 0.820 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2022 | 29 | 0.820 |
Why?
|
| Humans | 56 | 2023 | 14077 | 0.810 |
Why?
|
| Male | 37 | 2019 | 6489 | 0.800 |
Why?
|
| Drug Resistance, Viral | 7 | 2015 | 268 | 0.780 |
Why?
|
| Raltegravir Potassium | 2 | 2021 | 14 | 0.740 |
Why?
|
| Female | 37 | 2019 | 8751 | 0.700 |
Why?
|
| South Africa | 31 | 2019 | 7312 | 0.690 |
Why?
|
| CD4 Lymphocyte Count | 10 | 2019 | 654 | 0.660 |
Why?
|
| Nevirapine | 7 | 2012 | 146 | 0.540 |
Why?
|
| Antitubercular Agents | 4 | 2014 | 299 | 0.530 |
Why?
|
| Benzoxazines | 6 | 2013 | 119 | 0.520 |
Why?
|
| Drug Therapy, Combination | 9 | 2019 | 271 | 0.500 |
Why?
|
| Stavudine | 2 | 2013 | 78 | 0.440 |
Why?
|
| Iron, Dietary | 1 | 2012 | 2 | 0.430 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2011 | 320 | 0.430 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2012 | 21 | 0.420 |
Why?
|
| Dietary Supplements | 1 | 2012 | 40 | 0.420 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2009 | 194 | 0.410 |
Why?
|
| Developmental Disabilities | 1 | 2012 | 22 | 0.390 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2011 | 467 | 0.380 |
Why?
|
| Hospitalization | 2 | 2012 | 392 | 0.380 |
Why?
|
| Adolescent | 14 | 2023 | 2858 | 0.380 |
Why?
|
| Health Resources | 1 | 2011 | 65 | 0.380 |
Why?
|
| Body Height | 2 | 2012 | 51 | 0.370 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2010 | 16 | 0.360 |
Why?
|
| Body Weight | 2 | 2012 | 110 | 0.360 |
Why?
|
| Cohort Studies | 7 | 2015 | 939 | 0.340 |
Why?
|
| HIV Core Protein p24 | 2 | 2007 | 18 | 0.340 |
Why?
|
| Coinfection | 3 | 2019 | 268 | 0.330 |
Why?
|
| Pyrimidinones | 5 | 2011 | 24 | 0.310 |
Why?
|
| Retrospective Studies | 5 | 2014 | 767 | 0.290 |
Why?
|
| Alkynes | 6 | 2013 | 113 | 0.290 |
Why?
|
| Cyclopropanes | 6 | 2013 | 119 | 0.290 |
Why?
|
| RNA, Viral | 9 | 2011 | 303 | 0.280 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 153 | 0.280 |
Why?
|
| Treatment Outcome | 8 | 2012 | 867 | 0.270 |
Why?
|
| Time Factors | 7 | 2014 | 503 | 0.270 |
Why?
|
| Neonatal Screening | 1 | 2006 | 24 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 150 | 0.250 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2004 | 9 | 0.240 |
Why?
|
| Infant, Newborn | 9 | 2012 | 1410 | 0.240 |
Why?
|
| Treatment Failure | 3 | 2015 | 175 | 0.230 |
Why?
|
| Mutation, Missense | 3 | 2015 | 65 | 0.230 |
Why?
|
| Emotions | 1 | 2023 | 18 | 0.220 |
Why?
|
| Chronic Disease | 1 | 2023 | 100 | 0.210 |
Why?
|
| Oxazines | 1 | 2022 | 71 | 0.200 |
Why?
|
| Piperazines | 1 | 2022 | 73 | 0.200 |
Why?
|
| Weight Gain | 2 | 2015 | 73 | 0.200 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2022 | 76 | 0.200 |
Why?
|
| Pyridones | 1 | 2022 | 87 | 0.200 |
Why?
|
| Survival Analysis | 2 | 2012 | 149 | 0.200 |
Why?
|
| Genotype | 5 | 2015 | 430 | 0.190 |
Why?
|
| Risk Factors | 4 | 2014 | 1431 | 0.180 |
Why?
|
| Incidence | 3 | 2012 | 655 | 0.180 |
Why?
|
| Hospital Mortality | 1 | 2000 | 94 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2014 | 326 | 0.160 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 409 | 0.160 |
Why?
|
| Urban Population | 1 | 2000 | 246 | 0.160 |
Why?
|
| Nutritional Status | 2 | 2012 | 75 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1377 | 0.140 |
Why?
|
| Blood | 2 | 2007 | 51 | 0.140 |
Why?
|
| Molecular Sequence Data | 8 | 2011 | 263 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2014 | 132 | 0.130 |
Why?
|
| Prevalence | 3 | 2012 | 1149 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 137 | 0.130 |
Why?
|
| Logistic Models | 2 | 2014 | 252 | 0.130 |
Why?
|
| Lamivudine | 2 | 2013 | 86 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 367 | 0.120 |
Why?
|
| Poverty | 2 | 2015 | 149 | 0.120 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 54 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2012 | 1131 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 163 | 0.110 |
Why?
|
| Receptors, CXCR4 | 2 | 2011 | 28 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 63 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 34 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2013 | 29 | 0.110 |
Why?
|
| Dideoxynucleosides | 1 | 2013 | 29 | 0.110 |
Why?
|
| Receptors, CCR5 | 2 | 2011 | 54 | 0.110 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2012 | 40 | 0.100 |
Why?
|
| Nervous System | 1 | 2012 | 3 | 0.100 |
Why?
|
| Lipids | 1 | 2012 | 81 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 12 | 0.100 |
Why?
|
| Growth Disorders | 1 | 2012 | 56 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2012 | 464 | 0.100 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 6 | 0.100 |
Why?
|
| AIDS Dementia Complex | 1 | 2012 | 29 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 8 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 55 | 0.100 |
Why?
|
| Recurrence | 1 | 2011 | 27 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2011 | 44 | 0.100 |
Why?
|
| Malnutrition | 1 | 2012 | 53 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2011 | 3 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 8 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 5 | 0.090 |
Why?
|
| HIV Protease | 1 | 2011 | 21 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2001 | 21 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 41 | 0.090 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2011 | 113 | 0.090 |
Why?
|
| Neutrophils | 2 | 2001 | 53 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 124 | 0.090 |
Why?
|
| Pediatrics | 2 | 2007 | 16 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 96 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 532 | 0.090 |
Why?
|
| Maternal Exposure | 1 | 2010 | 14 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 23 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 15 | 0.090 |
Why?
|
| Reference Values | 3 | 2015 | 64 | 0.090 |
Why?
|
| Plasma | 1 | 2010 | 39 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 123 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2009 | 20 | 0.080 |
Why?
|
| Cause of Death | 2 | 2000 | 206 | 0.080 |
Why?
|
| Risk | 1 | 2009 | 87 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 33 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 38 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2010 | 507 | 0.080 |
Why?
|
| Mutation | 1 | 2010 | 299 | 0.080 |
Why?
|
| Pregnancy | 3 | 2010 | 1815 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 380 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2010 | 312 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 5 | 0.070 |
Why?
|
| HIV Envelope Protein gp160 | 2 | 2006 | 22 | 0.070 |
Why?
|
| Immunoassay | 1 | 2007 | 28 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 4 | 2011 | 180 | 0.070 |
Why?
|
| Genes, nef | 1 | 2007 | 2 | 0.070 |
Why?
|
| Phlebotomy | 1 | 2006 | 6 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2007 | 29 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 103 | 0.070 |
Why?
|
| Genes, gag | 1 | 2006 | 6 | 0.070 |
Why?
|
| Genes, env | 1 | 2006 | 9 | 0.070 |
Why?
|
| Desiccation | 1 | 2006 | 15 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 102 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 260 | 0.060 |
Why?
|
| Prejudice | 1 | 2005 | 8 | 0.060 |
Why?
|
| Communication Barriers | 1 | 2005 | 10 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 2007 | 139 | 0.060 |
Why?
|
| Truth Disclosure | 1 | 2005 | 18 | 0.060 |
Why?
|
| Drug Interactions | 3 | 2011 | 30 | 0.060 |
Why?
|
| Age Distribution | 2 | 2007 | 106 | 0.060 |
Why?
|
| Caregivers | 1 | 2005 | 66 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2001 | 40 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2006 | 243 | 0.060 |
Why?
|
| Siblings | 1 | 2003 | 2 | 0.060 |
Why?
|
| HIV Long-Term Survivors | 1 | 2003 | 8 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2003 | 64 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 45 | 0.050 |
Why?
|
| Australia | 1 | 2023 | 46 | 0.050 |
Why?
|
| Child Behavior | 1 | 2023 | 11 | 0.050 |
Why?
|
| Parents | 1 | 2023 | 29 | 0.050 |
Why?
|
| Phylogeny | 3 | 2011 | 231 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 22 | 0.050 |
Why?
|
| Gene Products, env | 1 | 2001 | 11 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2001 | 20 | 0.050 |
Why?
|
| L-Selectin | 1 | 2001 | 7 | 0.050 |
Why?
|
| Age Factors | 3 | 2014 | 364 | 0.050 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2001 | 4 | 0.050 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2001 | 4 | 0.050 |
Why?
|
| Receptors, Complement | 1 | 2001 | 3 | 0.050 |
Why?
|
| Complement C5a | 1 | 2001 | 3 | 0.050 |
Why?
|
| Cell Degranulation | 1 | 2001 | 7 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2001 | 22 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2001 | 23 | 0.050 |
Why?
|
| Patient Admission | 1 | 2000 | 11 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2000 | 52 | 0.050 |
Why?
|
| Disease Progression | 3 | 2007 | 154 | 0.040 |
Why?
|
| Viremia | 2 | 2011 | 66 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2011 | 35 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2000 | 92 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2011 | 26 | 0.040 |
Why?
|
| Phenotype | 2 | 2011 | 144 | 0.040 |
Why?
|
| Cell Line | 2 | 2007 | 92 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2007 | 17 | 0.030 |
Why?
|
| Neutralization Tests | 2 | 2007 | 106 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2007 | 27 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 17 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 29 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 171 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 183 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 184 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 23 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2014 | 210 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 77 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 29 | 0.020 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2011 | 3 | 0.020 |
Why?
|
| Receptors, Lipoxin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 27 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 137 | 0.020 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 49 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 4 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 6 | 0.020 |
Why?
|
| Ethionamide | 1 | 2010 | 9 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2010 | 54 | 0.020 |
Why?
|
| Isoniazid | 1 | 2010 | 110 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 82 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 145 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 25 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 55 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 1 | 0.020 |
Why?
|
| Salivary Gland Diseases | 1 | 2007 | 1 | 0.020 |
Why?
|
| Salivary Glands | 1 | 2007 | 3 | 0.020 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2007 | 8 | 0.020 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2007 | 28 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2007 | 13 | 0.020 |
Why?
|
| Mycoses | 1 | 2007 | 8 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 149 | 0.020 |
Why?
|
| Specialties, Surgical | 1 | 2007 | 4 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 8 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2007 | 103 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 89 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 42 | 0.020 |
Why?
|
| Proviruses | 1 | 2006 | 6 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2007 | 44 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2007 | 37 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2006 | 17 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2006 | 30 | 0.020 |
Why?
|
| Milk, Human | 1 | 2006 | 22 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2007 | 217 | 0.020 |
Why?
|
| Epitopes | 1 | 2006 | 97 | 0.020 |
Why?
|
| Neoplasms | 1 | 2007 | 141 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2006 | 119 | 0.020 |
Why?
|
| Focus Groups | 1 | 2005 | 180 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 2007 | 263 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 186 | 0.010 |
Why?
|
| Developing Countries | 1 | 2007 | 385 | 0.010 |
Why?
|
| Gene Products, rev | 1 | 2003 | 2 | 0.010 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 2 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2001 | 9 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 2001 | 10 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 27 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 96 | 0.010 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2001 | 4 | 0.010 |
Why?
|
| Adult | 1 | 2009 | 5664 | 0.010 |
Why?
|